These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 21813109

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.
    Bays HE, Goldberg RB, Truitt KE, Jones MR.
    Arch Intern Med; 2008 Oct 13; 168(18):1975-83. PubMed ID: 18852398
    [Abstract] [Full Text] [Related]

  • 4. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus.
    Henry RR, Aroda VR, Mudaliar S, Garvey WT, Chou HS, Jones MR.
    Diabetes Obes Metab; 2012 Jan 13; 14(1):40-6. PubMed ID: 21831167
    [Abstract] [Full Text] [Related]

  • 5. Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies.
    Bays HE.
    Endocr Pract; 2011 Jan 13; 17(6):933-8. PubMed ID: 21856592
    [Abstract] [Full Text] [Related]

  • 6. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.
    Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL.
    Clin Ther; 2007 Jan 13; 29(1):74-83. PubMed ID: 17379048
    [Abstract] [Full Text] [Related]

  • 7. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.
    Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, Turner SM, Protasio J, Riiff T, Hellerstein MK.
    Diabetologia; 2012 Feb 13; 55(2):432-42. PubMed ID: 22134839
    [Abstract] [Full Text] [Related]

  • 8. Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes.
    Rosenstock J, Hernandez-Triana E, Handelsman Y, Misir S, Jones MR.
    Postgrad Med; 2012 Jul 13; 124(4):14-20. PubMed ID: 22913890
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
    Goldberg RB, Fonseca VA, Truitt KE, Jones MR.
    Arch Intern Med; 2008 Jul 28; 168(14):1531-40. PubMed ID: 18663165
    [Abstract] [Full Text] [Related]

  • 10. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study.
    Schwartz SL, Lai YL, Xu J, Abby SL, Misir S, Jones MR, Nagendran S.
    Metab Syndr Relat Disord; 2010 Apr 28; 8(2):179-88. PubMed ID: 20059361
    [Abstract] [Full Text] [Related]

  • 11. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance.
    Rivers SM, Kane MP, Busch RS, Bakst G, Hamilton RA.
    Endocr Pract; 2007 Apr 28; 13(1):11-6. PubMed ID: 17360295
    [Abstract] [Full Text] [Related]

  • 12. Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.
    Florentin M, Liberopoulos EN, Rizos CV, Kei AA, Liamis G, Kostapanos MS, Elisaf MS.
    Metab Syndr Relat Disord; 2013 Jun 28; 11(3):152-6. PubMed ID: 23170931
    [Abstract] [Full Text] [Related]

  • 13. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes.
    Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai YL, Jin X, Misir S, Nagendran S, Jones MR.
    Endocr Pract; 2010 Jun 28; 16(4):629-40. PubMed ID: 20634175
    [Abstract] [Full Text] [Related]

  • 14. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis.
    Jialal I, Abby SL, Misir S, Nagendran S.
    Metab Syndr Relat Disord; 2009 Jun 28; 7(3):255-8. PubMed ID: 19344229
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.
    Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR.
    Diabetes Care; 2008 Aug 28; 31(8):1479-84. PubMed ID: 18458145
    [Abstract] [Full Text] [Related]

  • 18. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
    Davidson MH, Rooney M, Pollock E, Drucker J, Choy Y.
    J Clin Lipidol; 2013 Aug 28; 7(5):423-32. PubMed ID: 24079283
    [Abstract] [Full Text] [Related]

  • 19. Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus.
    Goldberg RB, Rosenson RS, Hernandez-Triana E, Misir S, Jones MR.
    J Clin Lipidol; 2012 Aug 28; 6(4):318-24. PubMed ID: 22836068
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.